Principal Investigator
Amer Beitinjaneh
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20240118
Clinical Trial Summary
A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (LuminICE-203)
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Contact Information
Phone Number
+1 (305) 2434624